Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.

Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ; PET study.

Brain. 2003 Feb;126(Pt 2):312-25.

PMID:
12538400
2.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
3.

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.

Arch Neurol. 1995 Dec;52(12):1183-90.

PMID:
7492293
4.

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.

J Neurol Sci. 1995 Oct;132(2):156-61.

PMID:
8543941
5.

Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO.

J Nucl Med. 2000 Jan;41(1):65-70.

6.

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.

Brain. 2004 Dec;127(Pt 12):2747-54. Epub 2004 Aug 25.

PMID:
15329355
7.

Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Günther I.

Brain. 1997 Dec;120 ( Pt 12):2187-95.

PMID:
9448574
8.
9.

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS.

Arch Neurol. 1990 Dec;47(12):1290-8.

PMID:
2123623
10.

Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study.

Thobois S, Fraix V, Savasta M, Costes N, Pollak P, Mertens P, Koudsie A, Le Bars D, Benabid AL, Broussolle E.

J Neurol. 2003 Oct;250(10):1219-23.

PMID:
14586606
11.

Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.

Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.

Brain. 2001 Apr;124(Pt 4):784-92.

PMID:
11287377
12.

Imaging in Parkinson's disease: the role of monoamines in behavior.

Brooks DJ, Piccini P.

Biol Psychiatry. 2006 May 15;59(10):908-18. Epub 2006 Apr 11. Review.

PMID:
16581032
13.

Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.

Ann Neurol. 1992 Feb;31(2):184-92.

PMID:
1575457
14.

Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.

Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.

Ann Neurol. 1999 Nov;46(5):723-31.

PMID:
10553989
15.

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.

Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ.

Brain. 2009 May;132(Pt 5):1366-75. doi: 10.1093/brain/awn337. Epub 2009 Jan 19.

PMID:
19153147
16.

Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.

Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T.

J Neurosurg. 2005 Dec;103(6):968-73.

PMID:
16381182
17.

Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.

Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D.

Neuroimage. 2004 Apr;21(4):1497-507.

PMID:
15050574
18.

Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys.

Ohnishi T, Hayashi T, Okabe S, Nonaka I, Matsuda H, Iida H, Imabayashi E, Watabe H, Miyake Y, Ogawa M, Teramoto N, Ohta Y, Ejima N, Sawada T, Ugawa Y.

Biol Psychiatry. 2004 Mar 1;55(5):484-9.

PMID:
15023576
19.

New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.

Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F.

J Neural Transm (Vienna). 2002 Oct;109(10):1265-74.

PMID:
12373560
20.

Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study.

Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Sakamoto M.

J Cereb Blood Flow Metab. 2002 Jun;22(6):746-52.

PMID:
12045673

Supplemental Content

Support Center